Jason Rhodes Sells 95,900 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 95,900 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $21.02, for a total transaction of $2,015,818.00. Following the transaction, the director directly owned 1,086,063 shares in the company, valued at approximately $22,829,044.26. This represents a 8.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $20.94 on Friday. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The stock has a market cap of $3.46 billion, a PE ratio of -6.50 and a beta of 1.09. The company’s fifty day moving average is $18.45 and its 200 day moving average is $18.11. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the business earned ($1.05) EPS. Research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics during the 1st quarter valued at about $26,000. Strs Ohio bought a new position in Dyne Therapeutics during the 4th quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC lifted its holdings in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DYN shares. Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Finally, Chardan Capital restated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.